newsfilter
← Latest News
PR Newswire·

Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through ...